<p>Arista Wealth Management LLC 在第二季度獲得了賽諾菲（NASDAQ:SNY - 免費報告）的新股份，根據其最近向 SEC 的披露。該基金購買了 7,890 股公司股票，價值約為 381,000 美元。</p>
<ul>
<li>分析師們對這些鮮為人知的生物製藥股票情有獨鍾</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也增加或減少了對該股票的持倉。Ameritas Advisory Services LLC 在第二季度獲得了價值 28,000 美元的賽諾菲新股份。Accent Capital Management LLC 在第一季度獲得了價值 29,000 美元的賽諾菲新股份。Eastern Bank 在第一季度將其賽諾菲持股增加了 121.0%。Eastern Bank 目前擁有 548 股公司股票，價值 30,000 美元，此前在上個季度又購買了 300 股。Banque Transatlantique SA 在第一季度獲得了價值約 33,000 美元的賽諾菲新股份。最後，Golden State Wealth Management LLC 在第一季度將其賽諾菲持股增加了 619.3%。Golden State Wealth Management LLC 目前擁有 633 股公司股票，價值 35,000 美元，此前在上個季度又購買了 545 股。14.04% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家股票分析師對該公司發佈了報告。德意志銀行在 9 月 2 日的報告中將賽諾菲的評級從 “持有” 上調至 “買入”。Wall Street Zen 在 8 月 2 日的研究報告中將賽諾菲的評級從 “持有” 上調至 “買入”。摩根士丹利在 9 月 8 日的研究報告中將賽諾菲的評級從 “同等權重” 上調至 “增持”，並將其目標價格從 56.00 美元上調至 58.00 美元。摩根大通在 8 月 8 日的研究報告中將賽諾菲的評級從 “中性” 上調至 “增持”。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對賽諾菲的 “持有（c）” 評級。兩位投資分析師給予該股票 “強烈買入” 評級，六位給予 “買入” 評級，兩位給予 “持有” 評級。根據 MarketBeat 的數據，賽諾菲目前的共識評級為 “買入”，平均目標價格為 62.67 美元。</p>
<ul>
<li>分析師認為這些股票的價值可能會翻倍</li>
</ul>
<p><strong>閲讀我們關於 SNY 的最新報告</strong></p>
<h2>賽諾菲股票表現</h2>
<p>SNY 的股票在週五開盤價為 50.62 美元。該公司的流動比率為 1.27，速動比率為 0.94，債務股本比率為 0.19。該公司的市值為 1243 億美元，市盈率為 12.17，PEG 比率為 1.22，貝塔值為 0.51。該股票的 50 日移動平均線為 48.49 美元，200 日移動平均線為 49.63 美元。賽諾菲的 12 個月低點為 44.62 美元，12 個月高點為 60.12 美元。</p>
<ul>
<li>Regeneron：它是價值與增長的完美生物科技股票嗎？</li>
</ul>
<p>賽諾菲（NASDAQ:SNY - 獲取免費報告）最後一次公佈季度財報是在 7 月 31 日。該公司報告每股收益為 0.90 美元，低於共識預期的 0.96 美元（差 0.06 美元）。賽諾菲的淨利潤率為 21.47%，股本回報率為 16.86%。該公司在本季度的收入為 113.4 億美元，而共識預期為 99.1 億美元。去年同期，該公司每股收益為 1.73 美元。賽諾菲本季度的收入同比下降了 7.0%。作為一個整體，賣方分析師預測賽諾菲在當前年度的每股收益將達到 4.36 美元。</p>
<h2>賽諾菲公司簡介</h2>
<p>（免費報告）</p>
<p>賽諾菲是一家醫療保健公司，專注於在美國、歐洲、加拿大及國際市場的治療解決方案的研究、開發、生產和營銷。它通過製藥、疫苗和消費者醫療保健三個部門運營。該公司提供特種護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過賽諾菲</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>三隻小盤股具有巨大的回報潛力</li>
<li>博通簽署 OpenAI 協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>WallStreetBets 是什麼，它們正在瞄準哪些股票？</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
<p><strong>想看看其他對沖基金持有的 SNY 嗎？</strong> 訪問 HoldingsChannel.com 以獲取賽諾菲（NASDAQ:SNY - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在賽諾菲嗎？</h2>
<p>在考慮賽諾菲之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而賽諾菲並不在名單上。</p>
<p>雖然賽諾菲目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽諾菲

賽諾菲集團

<p>根據 SEC 的披露，Arista Wealth Management LLC 在第二季度收購了 7,890 股賽諾菲（NASDAQ:SNY），價值約為 381,000 美元。其他機構投資者也增加了對賽諾菲的持股。分析師們已將賽諾菲的評級上調，普遍評級為 “買入”，平均目標價為 62.67 美元。賽諾菲的股票開盤價為 50.62 美元，市值為 1243 億美元。該公司報告上個季度每股收益為 0.90 美元，未達到預期，營收為 113.4 億美元，同比下降 7%</p>

<p>Arista Wealth Management LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 7,890 shares of the company's stock, valued at approximately $381,000.</p>
<div class="lb-trans"><p>Arista Wealth Management LLC 在第二季度獲得了賽諾菲（NASDAQ:SNY - 免費報告）的新股份，根據其最近向 SEC 的披露。該基金購買了 7,890 股公司股票，價值約為 381,000 美元。</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師們對這些鮮為人知的生物製藥股票情有獨鍾</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi during the 2nd quarter worth $28,000. Accent Capital Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth $29,000. Eastern Bank raised its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new position in Sanofi in the 1st quarter worth about $33,000. Finally, Golden State Wealth Management LLC increased its holdings in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after purchasing an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也增加或減少了對該股票的持倉。Ameritas Advisory Services LLC 在第二季度獲得了價值 28,000 美元的賽諾菲新股份。Accent Capital Management LLC 在第一季度獲得了價值 29,000 美元的賽諾菲新股份。Eastern Bank 在第一季度將其賽諾菲持股增加了 121.0%。Eastern Bank 目前擁有 548 股公司股票，價值 30,000 美元，此前在上個季度又購買了 300 股。Banque Transatlantique SA 在第一季度獲得了價值約 33,000 美元的賽諾菲新股份。最後，Golden State Wealth Management LLC 在第一季度將其賽諾菲持股增加了 619.3%。Golden State Wealth Management LLC 目前擁有 633 股公司股票，價值 35,000 美元，此前在上個季度又購買了 545 股。14.04% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, September 2nd. Wall Street Zen upgraded Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Morgan Stanley upgraded Sanofi from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and upped their target price for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase &amp; Co. upgraded Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Sanofi in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Sanofi presently has a consensus rating of &#34;Buy&#34; and an average price target of $62.67.</p>
<div class="lb-trans"><p>多家股票分析師對該公司發佈了報告。德意志銀行在 9 月 2 日的報告中將賽諾菲的評級從 “持有” 上調至 “買入”。Wall Street Zen 在 8 月 2 日的研究報告中將賽諾菲的評級從 “持有” 上調至 “買入”。摩根士丹利在 9 月 8 日的研究報告中將賽諾菲的評級從 “同等權重” 上調至 “增持”，並將其目標價格從 56.00 美元上調至 58.00 美元。摩根大通在 8 月 8 日的研究報告中將賽諾菲的評級從 “中性” 上調至 “增持”。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對賽諾菲的 “持有（c）” 評級。兩位投資分析師給予該股票 “強烈買入” 評級，六位給予 “買入” 評級，兩位給予 “持有” 評級。根據 MarketBeat 的數據，賽諾菲目前的共識評級為 “買入”，平均目標價格為 62.67 美元。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師認為這些股票的價值可能會翻倍</li>
</ul>
</div><p><strong>Read Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 SNY 的最新報告</strong></p>
</div><h2>Sanofi Stock Performance</h2>
<div class="lb-trans"><h2>賽諾菲股票表現</h2>
</div><p>Shares of SNY opened at $50.62 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $124.30 billion, a price-to-earnings ratio of 12.17, a PEG ratio of 1.22 and a beta of 0.51. The stock has a 50 day moving average of $48.49 and a 200 day moving average of $49.63. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.</p>
<div class="lb-trans"><p>SNY 的股票在週五開盤價為 50.62 美元。該公司的流動比率為 1.27，速動比率為 0.94，債務股本比率為 0.19。該公司的市值為 1243 億美元，市盈率為 12.17，PEG 比率為 1.22，貝塔值為 0.51。該股票的 50 日移動平均線為 48.49 美元，200 日移動平均線為 49.63 美元。賽諾菲的 12 個月低點為 44.62 美元，12 個月高點為 60.12 美元。</p>
</div><ul>
<li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li>
</ul>
<div class="lb-trans"><ul>
<li>Regeneron：它是價值與增長的完美生物科技股票嗎？</li>
</ul>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the company posted $1.73 earnings per share. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>賽諾菲（NASDAQ:SNY - 獲取免費報告）最後一次公佈季度財報是在 7 月 31 日。該公司報告每股收益為 0.90 美元，低於共識預期的 0.96 美元（差 0.06 美元）。賽諾菲的淨利潤率為 21.47%，股本回報率為 16.86%。該公司在本季度的收入為 113.4 億美元，而共識預期為 99.1 億美元。去年同期，該公司每股收益為 1.73 美元。賽諾菲本季度的收入同比下降了 7.0%。作為一個整體，賣方分析師預測賽諾菲在當前年度的每股收益將達到 4.36 美元。</p>
</div><h2>Sanofi Company Profile</h2>
<div class="lb-trans"><h2>賽諾菲公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>賽諾菲是一家醫療保健公司，專注於在美國、歐洲、加拿大及國際市場的治療解決方案的研究、開發、生產和營銷。它通過製藥、疫苗和消費者醫療保健三個部門運營。該公司提供特種護理，如 DUPIXENT、神經學和免疫學、罕見疾病、腫瘤學和罕見血液疾病；糖尿病和心血管疾病的藥物；以及已建立的處方產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Sanofi</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過賽諾菲</li>
<li>如何計算退休收入：MarketBeat 的計算器</li>
<li>這家 AI 芯片巨頭可能是市場下一個大贏家</li>
<li>三隻小盤股具有巨大的回報潛力</li>
<li>博通簽署 OpenAI 協議：為什麼這對 AVGO 股票是一個巨大的勝利</li>
<li>WallStreetBets 是什麼，它們正在瞄準哪些股票？</li>
<li>機構正在推動 CrowdStrike 的下一輪上漲</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 SNY 嗎？</strong> 訪問 HoldingsChannel.com 以獲取賽諾菲（NASDAQ:SNY - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sanofi Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在賽諾菲嗎？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮賽諾菲之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而賽諾菲並不在名單上。</p>
</div><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽諾菲目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Arista Wealth Management LLC 收購了 7,890 股賽諾菲股票 $SNY